Yuvraj_pawp, Author at Pharma Advancement

Vyome Biosciences Presents Research Data on Development of Novel Antibiotics and Antifungal Agents to American Society of Microbiology

30th September 2015

Vyome Biosciences, a dermatology based innovative bio-pharmaceutical company, which is pioneering the development of next generation antibiotics and antifungal agents...

Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts

by Yuvraj_pawp

6th May 2015

Today announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts – a strategic location...

Long-Term, 7-Year Study of Nulojix® Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant

by Yuvraj_pawp

6th May 2015

Bristol-Myers Squibb Company announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial (BENEFIT) in kidney...

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference

by Yuvraj_pawp

4th May 2015

The Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, in Las Vegas. Doug Manion,...

Bristol-Myers Squibb Prices €1.15 Billion of Senior Notes

by Yuvraj_pawp

29th April 2015

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to sell €1.15 billion of senior unsecured notes: €575,000,000 in...

Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference

by Yuvraj_pawp

29th April 2015

Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference 4/29/15 will take part in the Deutsche Bank Global...

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

by Yuvraj_pawp

29th April 2015

Application includes CheckMate -066, a clinical trial of Opdivo vs. dacarbazine chemotherapy in patients who had not received prior therapy...

Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities

by Yuvraj_pawp

28th April 2015

Announcement today that it has commenced a cash tender offer for up to $400 million aggregate principal amount (the “tender...

Bristol-Myers Squibb Reports First Quarter Financial Results

by Yuvraj_pawp

28th April 2015

Reports Revenues of $4.0 Billion in the First Quarter Posts First Quarter GAAP and Non-GAAP EPS of $0.71 Achieves Key...

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

by Yuvraj_pawp

25th April 2015

Today announced that primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of...

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Yuvraj_pawp

Vyome Biosciences Presents Research Data on Development of Novel Antibiotics and Antifungal Agents to American Society of Microbiology

Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts

Long-Term, 7-Year Study of Nulojix® Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference

Bristol-Myers Squibb Prices €1.15 Billion of Senior Notes

Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities

Bristol-Myers Squibb Reports First Quarter Financial Results

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

Qucik Links

About Us

Subscribe Us

System

Resources

Retrieve your password